Neumora Therapeutics (NMRA) Long-Term Investments (2022 - 2024)

Neumora Therapeutics' Long-Term Investments history runs 3 years deep, the most recent figure standing at $302000.0 for Q1 2024.

• On a quarterly basis, Long-Term Investments changed N/A year-over-year to $302000.0 in Q1 2024; TTM through Mar 2024 was $302000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $9.8 million, down 58.13% from the prior year.
• Long-Term Investments retreated to $302000.0 in Q1 2024 per NMRA's latest filing, from $9.8 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $23.5 million in Q4 2022 and bottomed at $302000.0 in Q1 2024.
• The 3-year median for Long-Term Investments is $9.9 million (2023), against an average of $10.9 million.
• Biggest YoY gain for Long-Term Investments was 58.13% in 2023; the steepest drop was 58.13% in 2023.
• Year by year, Long-Term Investments stood at $23.5 million in 2022, then plunged by 58.13% to $9.8 million in 2023, then tumbled by 96.93% to $302000.0 in 2024.
• Per Business Quant, the three latest NMRA Long-Term Investments figures stand at $302000.0 (Q1 2024), $9.8 million (Q4 2023), and $9.9 million (Q3 2023).